Patents by Inventor Friedrich Dorner

Friedrich Dorner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stable factor VIII/vWF-complex
    Patent number: 6924151
    Abstract: There are disclosed a stable factor VIII/vWF-complex, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing this complex.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: August 2, 2005
    Assignee: Baxter Aktiengesellschaft
    Inventors: Bernhard Fischer, Artur Mitterer, Friedrich Dorner, Johann Eibl
  • Nucleic acids encoding factor X deletion mutants and analogues thereof
    Patent number: 6905846
    Abstract: Nucleic acids encoding factor X? analogues having a deletion of amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg 179 are provided.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: June 14, 2005
    Assignee: Baxter Aktiengesellschaft
    Inventors: Michele Himmelspach, Michael Pfleiderer, Falko-Guenter Falkner, Johann Eibl, Friedrich Dorner, Uwe Schlokat
  • Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
    Patent number: 6872550
    Abstract: A novel approach to Borrelia vaccine formulation taking into account serological, genotypic and epidemiological information by which OspC proteins from different strains of B. burgdorferi are grouped together. OspC antigens are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest number of antigens.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: March 29, 2005
    Assignee: Baxter Vaccine AG
    Inventors: Ian Livey, Brian Crowe, Friedrich Dorner
  • Inactivated influenza virus vaccine for nasal or oral application
    Patent number: 6861244
    Abstract: The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: March 1, 2005
    Assignee: Baxter Healthcare S.A.
    Inventors: Noel Barrett, Otfried Kistner, Marijan Gerencer, Friedrich Dorner
  • Method of large scale production of Hepatitis A virus
    Patent number: 6855535
    Abstract: The present invention provides methods of large scale production of Hepatitis A Virus (HAV) on VERO cells bound to microcarrier. The invention also provides for methods of isolation of HAV from the cell culture supernatant of HAV infected VERO cells.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: February 15, 2005
    Assignee: Baxter Healthcare S.A.
    Inventors: Heidi Meyer, Manfred Reiter, Wolfgang Mundt, Noel Barrett, Friedrich Dorner
  • Method for purifying factor VIII/vWF company by cation-exchange chromatography
    Patent number: 6831159
    Abstract: Methods for recovering factor VIII/vWF-complex that involve binding factor VIII/vWF-complex from a protein solution to a cation exchanger and recovering factor VIII/vWF-complex by step-wise elution are disclosed. The recovered complex contains high-molecular vWF multimers. Compositions containing factor VIII/vWF-complex as purified by cation exchange chromatography are also provided.
    Type: Grant
    Filed: May 8, 2000
    Date of Patent: December 14, 2004
    Assignee: Baxter Aktiengesellschaft
    Inventors: Artur Mitterer, Bernhard Fischer, Öyvind L. Schönberger, Kathrin Thomas-Urban, Friedrich Dorner, Johann Eibl
  • Inactivated influenza virus vaccine for nasal or oral application
    Publication number: 20040096464
    Abstract: The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response.
    Type: Application
    Filed: August 13, 2003
    Publication date: May 20, 2004
    Applicant: Baxter Healthcare S.A.
    Inventors: Noel Barrett, Otfried Kistner, Marijan Gerencer, Friedrich Dorner
  • Medium for the protein-free and serum-free cultivation of cells
    Publication number: 20030203448
    Abstract: A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate.
    Type: Application
    Filed: April 1, 2003
    Publication date: October 30, 2003
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner, Leopold Grillberger, Artur Mitterer
  • Inactivated influenza virus vaccine for nasal or oral application
    Patent number: 6635246
    Abstract: The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: October 21, 2003
    Assignee: Baxter Healthcare S.A.
    Inventors: Noel Barrett, Otfried Kistner, Marijan Gerencer, Friedrich Dorner
  • Factor X analogues having a modified protease cleavage site
    Publication number: 20030181381
    Abstract: Factor X analogues having a modification in the region of the natural Factor Xa activation cleavage site, said modification representing a processing site of a protease not naturally cleaving in this region of the Factor X sequence, preparations containing the Factor X analogues according to the invention, and processes for the preparation thereof are described.
    Type: Application
    Filed: April 4, 2003
    Publication date: September 25, 2003
    Inventors: Michele Himmelspach, Uwe Schlokat, Friedrich Dorner, Andreas Fisch, Johann Eibl
  • Factor X deletion mutants and analogues thereof
    Publication number: 20030138914
    Abstract: Factor X&Dgr; analogues having a deletion of amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg179, preparations containing these factor X&Dgr; analogues, and processes for the preparation thereof are described.
    Type: Application
    Filed: January 21, 2003
    Publication date: July 24, 2003
    Inventors: Michele Himmelspach, Michael Pfleiderer, Falko-Guenter Falkner, Johann Eibl, Friedrich Dorner, Uwe Schlokat
  • Method of recovering highly purified vWF or factor VIII/vWF-complex
    Patent number: 6579723
    Abstract: A method for purifying factor VIII/vWF complex or free vWF by immunoaffinity chromatography in a form suitable for use as a medicament. Factor VIII/vWF complex or free vWF is recovered from an immunoaffinity adsorbent by using an eluting agent containing a zwitterionic species. The presence of the zwitterionic species allows for the use of mild conditions throughout the preparation, facilitating retention of molecular integrity, activity, and incorporation of the recovered proteins into pharmaceutical preparations without the need for additional stabilizers or preservatives.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: June 17, 2003
    Assignee: Baxter Aktiengesellschaft
    Inventors: Artur Mitterer, Christian Fiedler, Bernhard Fischer, Friedrich Dorner, Johann Eibl
  • Method of large scale production of Hepatitis A Virus
    Publication number: 20030108861
    Abstract: The present invention provides methods of large scale production of Hepatitis A Virus (HAV) on VERO cells bound to microcarrier. The invention also provides for methods of isolation of HAV from the cell culture supernatant of HAV infected VERO cells.
    Type: Application
    Filed: December 10, 2001
    Publication date: June 12, 2003
    Inventors: Heidi Meyer, Manfred Reiter, Wolfgang Mundt, Noel Barrett, Friedrich Dorner
  • Enveloped virus vaccine and method for production
    Publication number: 20030108859
    Abstract: The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen.
    Type: Application
    Filed: December 10, 2001
    Publication date: June 12, 2003
    Inventors: Otfried Kistner, Manfred Reiter, Axel Bruehmann, Noel Barrett, Wolfgang Mundt, Friedrich Dorner
  • Factor X analogues with a modified protease cleavage site
    Patent number: 6573071
    Abstract: Factor X analogues having a modification in the region of the natural Factor Xa activation cleavage site, said modification representing a processing site of a protease not naturally cleaving in this region of the Factor X sequence, preparations containing the Factor X analogues according to the invention, and processes for the preparation thereof are described.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: June 3, 2003
    Assignee: Baxter Aktiengesellschaft
    Inventors: Michele Himmelspach, Uwe Schlokat, Friedrich Dorner, Andreas Fisch, Johann Eibl
  • Factor X deletion mutants and analogues thereof
    Patent number: 6562598
    Abstract: Factor X&Dgr; analogues are provided, as well as pharmaceutical preparations containing such analogues and methods of preparing such analogues. The factor X&Dgr; analogues have a deletion of the amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg179 of the factor X amino acid sequence. Such analogues can include a processing site not normally present in factor X, thus allowing for selective conversion of the analogue to an active form. The analogues and preparations have utility in the treatment of a number of blood coagulation disorders.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: May 13, 2003
    Assignee: Baxter Aktiengesellschaft
    Inventors: Michele Himmelspach, Michael Pfleiderer, Falko-Guenter Falkner, Johann Eibl, Friedrich Dorner, Uwe Schlokat
  • Immunogenic formulation of OSPC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
    Patent number: 6486130
    Abstract: A novel approach to Borrelia vaccine formulation taking into account serological, genotypic and epidemiological information by which OspC proteins from different strains of B burgdorferi are grouped together. OspC antigens are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest number of antigens.
    Type: Grant
    Filed: June 27, 1996
    Date of Patent: November 26, 2002
    Assignee: Baxter Vaccine AG
    Inventors: Ian Livey, Brian Crowe, Friedrich Dorner
  • Recombinant cell clones having increased stability and methods of making and using the same
    Patent number: 6475725
    Abstract: Disclosed are stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Grant
    Filed: June 2, 1999
    Date of Patent: November 5, 2002
    Assignee: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Method for depleting viral and molecular pathogens in a biological material
    Patent number: 6465170
    Abstract: A method for depleting viral and molecular pathogens in a biological material containing one or several biological substances to be recovered is disclosed, wherein the biological material is admixed with an organic solvent, the solvent-admixed biological material is contacted with an ion exchanger, wherein the pathogens are adsorbed on the ion exchanger material, and at least one of the biological substances to be recovered does not interact or interacts only slightly with the ion exchanger, and the ion exchanger with the pathogens adsorbed thereon is sesparated from the biological material, a virus-depleted preparation of the biological substance being recovered.
    Type: Grant
    Filed: August 20, 2001
    Date of Patent: October 15, 2002
    Assignee: Baxter Aktiengesellschaft
    Inventors: Johann Eibl, Friedrich Dorner, Noel Barrett, Gerhard Polsler
  • Purification of von-Willebrand factor by cation exchanger chromatography
    Patent number: 6465624
    Abstract: Disclosed are a method of recovering vWF in which vWF at a low salt concentration is bound to a cation exchanger and vWF having a high specific activity is recovered by fractionated elution, as well as a preparation having purified vWF obtainable by this method.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 15, 2002
    Assignee: Baxter Aktiengesellschaft
    Inventors: Bernhard Fischer, Öyvind L. Schönberger, Artur Mitterer, Christian Fiedler, Friedrich Dorner, Johann Eibl